Leerink Partnrs Forecasts Scholar Rock Q3 Earnings

Key Points

• Analysts at Leerink Partners predict Scholar Rock will report a Q3 2025 loss of ($0.99) per share, with full-year earnings expectations at ($2.42) per share.
• Scholar Rock's Q2 earnings missed expectations, recording ($0.98) EPS, and a range of analysts maintain a "Strong-Buy" and "Outperform" rating with target prices around $46.33.
• Institutional ownership of Scholar Rock stands at 91.08%, indicating strong confidence among large investors in the company's stock.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Scholar Rock in a research report issued on Monday, September 15th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.99) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Scholar Rock's Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.56) EPS, FY2026 earnings at ($2.17) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.74 EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same period in the previous year, the company earned ($0.60) earnings per share.

Several other research firms have also recently weighed in on SRRK. Lifesci Capital upgraded Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Raymond James Financial set a $53.00 target price on Scholar Rock and gave the stock a "strong-buy" rating in a report on Wednesday, July 30th. Jefferies Financial Group started coverage on Scholar Rock in a report on Thursday, August 21st. They issued a "buy" rating and a $50.00 target price for the company. Barclays initiated coverage on Scholar Rock in a report on Wednesday. They issued an "overweight" rating and a $45.00 target price for the company. Finally, Wedbush restated an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, June 18th. Three research analysts have rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. According to data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and an average price target of $46.20.

Scholar Rock Price Performance

SRRK traded down $1.64 on Wednesday, hitting $30.84. 3,347,035 shares of the company's stock traded hands, compared to its average volume of 1,626,993. The company's 50 day simple moving average is $34.69 and its 200-day simple moving average is $33.09. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -10.60 and a beta of 0.36. Scholar Rock has a one year low of $6.76 and a one year high of $46.98. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.21.

Insider Activity

In related news, insider Mo Qatanani sold 24,066 shares of Scholar Rock stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total transaction of $828,833.04. Following the transaction, the insider owned 115,495 shares in the company, valued at approximately $3,977,647.80. This trade represents a 17.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total value of $32,725.18. Following the completion of the sale, the director owned 33,914 shares in the company, valued at $1,103,222.42. This represents a 2.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 70,838 shares of company stock worth $2,438,562 over the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Scholar Rock

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans acquired a new stake in shares of Scholar Rock in the second quarter valued at $639,000. Tower Research Capital LLC TRC raised its stake in Scholar Rock by 288.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,115 shares of the company's stock valued at $323,000 after acquiring an additional 6,768 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in Scholar Rock by 6.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company's stock valued at $395,000 after acquiring an additional 710 shares during the last quarter. Vestal Point Capital LP increased its position in Scholar Rock by 15.4% during the 2nd quarter. Vestal Point Capital LP now owns 1,500,000 shares of the company's stock worth $53,130,000 after purchasing an additional 200,000 shares during the period. Finally, Eventide Asset Management LLC increased its position in Scholar Rock by 9.5% during the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company's stock worth $103,192,000 after purchasing an additional 251,638 shares during the period. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.